吉西他滨联合长春瑞滨用于转移性鼻咽癌二线治疗的临床观察  

The Clinical Observation of Gemcitabine Plus Vinorelbine for Second-line Treatment of Metastatic Nasopharyngeal

作　　者：马慧敏[1] 林燕锋[1] 袁霞[1] 

机构地区：[1]惠州市中心人民医院肿瘤内科,广东惠州516000

出　　处：《中国医药指南》2013年第20期71-73,共3页Guide of China Medicine

摘　　要：目的评价吉西他滨联合长春瑞滨二线治疗晚期鼻咽癌的近期疗效和毒性反应。方法 38例均为含顺铂方案一线化疗失败的晚期鼻咽癌患者,接受吉西他滨联合长春瑞滨方案治疗,吉西他滨1000mg/m2静脉滴注30min,d1、d8,长春瑞滨25mg/m2静脉推注,d1、d8,每21d重复一次。结果 38例共完成167个周期的治疗,中位数4周期,范围2~6周期,均可评价疗效,其中CR5例,PR20例,SD9例,PD4例,客观有效率（CR＋PR）65.8%,中位缓解时间5.6个月。中位疾病进展时间6.2个月,中位生存期16.2个月;1年生存率65.8%,2年生存率44.7%。不良反应主要为Ⅰ~Ⅱ度骨髓抑制、末梢神经毒性及胃肠道反应。结论吉西他滨联合长春瑞滨二线治疗转移性鼻咽癌患者,初步观察疗效可,毒副作用可耐受,值得临床进一步研究。Objective To evaluate gemcitabine plus vinorelbine second-line treatment of metastatic nasopharyngeal efficacy and toxicity. Method 38 cases are cisplatin-containing first-line chemotherapy failure in patients with metastatic nasopharyngeal, receiving gemcitabine plus vinorelbine regimen, gemcitabine 1000 mg/m2 intravenously 30 min, dl, d8, vinorelbine 25mg/m2 intravenous bolus dl, d8, repeated every 21 days time. Results 38 patients completed 167 cycles of treatment, with a median 4 cycles, range 2-6 cycles, can be evaluated, CR5 cases, the PR20 cases, SD9 patients, PD4 patients, the objective response rate （CR＋PR） 65.8%. The median duration of 5.6 months. The median time to progression was 6.2 months, with a median survival time of 16.2 months; 1 year survival rate was 65.8%, 2 year survival rate was 44.7%. The main adverse reactions of I - II degree of bone marrow suppression, peripheral neurotoxicity and gastrointestinal reactions. Conclusion Vinorelbine, gemcitabine combined with second-line treatment of metastatic nasopharyngeal carcinoma lpatients, preliminary observations have a certain effect, toxicity is tolerated, is worthy of further study.

关 键 词：吉西他滨 长春瑞滨 转移性鼻咽癌 化学治疗 

分 类 号：R739.63[医药卫生—肿瘤]